Modality,Phase,CQA,Test Methods,Justification,Regulatory Source,Control Action
mAb,Phase 1,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm primary structure and identity,ICH Q6B 4.1,Specification
mAb,Phase 2,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm primary structure and identity,ICH Q6B 4.1,Specification
mAb,Phase 3,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm primary structure and identity,ICH Q6B 4.1,Specification
mAb,Commercial,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm primary structure and identity,ICH Q6B 4.1,Specification
mAb,Phase 1,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
mAb,Phase 2,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
mAb,Phase 3,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
mAb,Commercial,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
mAb,Phase 1,Potency,"Binding Assay, Bioassay (ADCC, CDC)",Confirm biological activity,ICH Q6B 4.3,Specification
mAb,Phase 2,Potency,"Binding Assay, Bioassay (ADCC, CDC)",Confirm biological activity,ICH Q6B 4.3,Specification
mAb,Phase 3,Potency,"Binding Assay, Bioassay (ADCC, CDC)",Confirm biological activity,ICH Q6B 4.3,Specification
mAb,Commercial,Potency,"Binding Assay, Bioassay (ADCC, CDC)",Confirm biological activity,ICH Q6B 4.3,Specification
mAb,Phase 1,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform variation,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform variation,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform variation,ICH Q6B 4.2,Specification
mAb,Commercial,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform variation,ICH Q6B 4.2,Specification
mAb,Phase 1,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform distribution,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform distribution,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform distribution,ICH Q6B 4.2,Specification
mAb,Commercial,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform distribution,ICH Q6B 4.2,Specification
mAb,Phase 1,Deamidation,Peptide Mapping LC-MS,Detect stability-related PTM,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Deamidation,Peptide Mapping LC-MS,Detect stability-related PTM,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Deamidation,Peptide Mapping LC-MS,Detect stability-related PTM,ICH Q6B 4.2,Specification
mAb,Commercial,Deamidation,Peptide Mapping LC-MS,Detect stability-related PTM,ICH Q6B 4.2,Specification
mAb,Phase 1,Oxidation,Peptide Mapping LC-MS,Monitor oxidation hotspots,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Oxidation,Peptide Mapping LC-MS,Monitor oxidation hotspots,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Oxidation,Peptide Mapping LC-MS,Monitor oxidation hotspots,ICH Q6B 4.2,Specification
mAb,Commercial,Oxidation,Peptide Mapping LC-MS,Monitor oxidation hotspots,ICH Q6B 4.2,Specification
mAb,Phase 1,Fragmentation,SEC-UPLC,Detect low molecular weight species,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Fragmentation,SEC-UPLC,Detect low molecular weight species,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Fragmentation,SEC-UPLC,Detect low molecular weight species,ICH Q6B 4.2,Specification
mAb,Commercial,Fragmentation,SEC-UPLC,Detect low molecular weight species,ICH Q6B 4.2,Specification
mAb,Phase 1,Host Cell Protein,ELISA,Control process residual proteins,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Host Cell Protein,ELISA,Control process residual proteins,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Host Cell Protein,ELISA,Control process residual proteins,ICH Q6B 4.2,Specification
mAb,Commercial,Host Cell Protein,ELISA,Control process residual proteins,ICH Q6B 4.2,Specification
mAb,Phase 1,Host Cell DNA,qPCR,Control process residual DNA,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 2,Host Cell DNA,qPCR,Control process residual DNA,ICH Q6B 4.2,Trend Monitoring
mAb,Phase 3,Host Cell DNA,qPCR,Control process residual DNA,ICH Q6B 4.2,Specification
mAb,Commercial,Host Cell DNA,qPCR,Control process residual DNA,ICH Q6B 4.2,Specification
mAb,Phase 1,Sterility,USP <71>,Ensure sterility of product,USP <71>,Specification
mAb,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mAb,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mAb,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mAb,Phase 2,Sterility,USP <71>,Ensure sterility of product,USP <71>,Specification
mAb,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mAb,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mAb,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mAb,Phase 3,Sterility,USP <71>,Ensure sterility of product,USP <71>,Specification
mAb,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mAb,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mAb,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mAb,Commercial,Sterility,USP <71>,Ensure sterility of product,USP <71>,Specification
mAb,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mAb,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mAb,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
Fusion Protein,Phase 1,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm correct primary structure and sequence of fusion protein,ICH Q6B 4.1,Specification
Fusion Protein,Phase 2,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm correct primary structure and sequence of fusion protein,ICH Q6B 4.1,Specification
Fusion Protein,Phase 3,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm correct primary structure and sequence of fusion protein,ICH Q6B 4.1,Specification
Fusion Protein,Commercial,Identity,"Peptide Mapping, ELISA, Intact Mass, N-terminal Sequencing",Confirm correct primary structure and sequence of fusion protein,ICH Q6B 4.1,Specification
Fusion Protein,Phase 1,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
Fusion Protein,Phase 2,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
Fusion Protein,Phase 3,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis","Detect aggregates, fragments, purity profile",ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Potency,"Binding Assay, Cell-Based Bioassay",Confirm biological activity of the fusion construct,ICH Q6B 4.3,Specification
Fusion Protein,Phase 2,Potency,"Binding Assay, Cell-Based Bioassay",Confirm biological activity of the fusion construct,ICH Q6B 4.3,Specification
Fusion Protein,Phase 3,Potency,"Binding Assay, Cell-Based Bioassay",Confirm biological activity of the fusion construct,ICH Q6B 4.3,Specification
Fusion Protein,Commercial,Potency,"Binding Assay, Cell-Based Bioassay",Confirm biological activity of the fusion construct,ICH Q6B 4.3,Specification
Fusion Protein,Phase 1,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform heterogeneity for fusion protein function and stability,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform heterogeneity for fusion protein function and stability,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform heterogeneity for fusion protein function and stability,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Glycosylation Profile,"HILIC-UPLC, LC-MS",Monitor glycoform heterogeneity for fusion protein function and stability,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect charge heterogeneity due to post-translational modifications,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect charge heterogeneity due to post-translational modifications,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect charge heterogeneity due to post-translational modifications,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect charge heterogeneity due to post-translational modifications,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Oxidation,Peptide Mapping LC-MS,Monitor oxidation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Oxidation,Peptide Mapping LC-MS,Monitor oxidation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Oxidation,Peptide Mapping LC-MS,Monitor oxidation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Oxidation,Peptide Mapping LC-MS,Monitor oxidation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Deamidation,Peptide Mapping LC-MS,Monitor deamidation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Deamidation,Peptide Mapping LC-MS,Monitor deamidation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Deamidation,Peptide Mapping LC-MS,Monitor deamidation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Deamidation,Peptide Mapping LC-MS,Monitor deamidation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Fragmentation,SEC-UPLC,Monitor fragmentation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Fragmentation,SEC-UPLC,Monitor fragmentation as stability-indicating degradation product,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Fragmentation,SEC-UPLC,Monitor fragmentation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Fragmentation,SEC-UPLC,Monitor fragmentation as stability-indicating degradation product,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Host Cell Protein,ELISA,Control process residual impurities,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Host Cell Protein,ELISA,Control process residual impurities,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Host Cell Protein,ELISA,Control process residual impurities,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Host Cell Protein,ELISA,Control process residual impurities,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Host Cell DNA,qPCR,Control process residual impurities,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 2,Host Cell DNA,qPCR,Control process residual impurities,ICH Q6B 4.2,Trend Monitoring
Fusion Protein,Phase 3,Host Cell DNA,qPCR,Control process residual impurities,ICH Q6B 4.2,Specification
Fusion Protein,Commercial,Host Cell DNA,qPCR,Control process residual impurities,ICH Q6B 4.2,Specification
Fusion Protein,Phase 1,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
Fusion Protein,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
Fusion Protein,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
Fusion Protein,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
Fusion Protein,Phase 2,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
Fusion Protein,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
Fusion Protein,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
Fusion Protein,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
Fusion Protein,Phase 3,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
Fusion Protein,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
Fusion Protein,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
Fusion Protein,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
Fusion Protein,Commercial,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
Fusion Protein,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
Fusion Protein,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
Fusion Protein,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
AAV,Phase 1,Identity,"Capsid Protein Analysis (LC-MS), Genome Sequencing, Peptide Mapping",Confirm correct viral vector genome and capsid identity,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 2,Identity,"Capsid Protein Analysis (LC-MS), Genome Sequencing, Peptide Mapping",Confirm correct viral vector genome and capsid identity,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 3,Identity,"Capsid Protein Analysis (LC-MS), Genome Sequencing, Peptide Mapping",Confirm correct viral vector genome and capsid identity,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Identity,"Capsid Protein Analysis (LC-MS), Genome Sequencing, Peptide Mapping",Confirm correct viral vector genome and capsid identity,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Purity,"SEC, SDS-PAGE, CE-SDS, Silver Staining",Assess product purity and protein impurities,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 2,Purity,"SEC, SDS-PAGE, CE-SDS, Silver Staining",Assess product purity and protein impurities,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 3,Purity,"SEC, SDS-PAGE, CE-SDS, Silver Staining",Assess product purity and protein impurities,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Purity,"SEC, SDS-PAGE, CE-SDS, Silver Staining",Assess product purity and protein impurities,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Potency,"In Vitro Infectivity Assay, Transduction Assay, Reporter Gene Expression",Confirm biological activity and gene transfer function,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 2,Potency,"In Vitro Infectivity Assay, Transduction Assay, Reporter Gene Expression",Confirm biological activity and gene transfer function,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 3,Potency,"In Vitro Infectivity Assay, Transduction Assay, Reporter Gene Expression",Confirm biological activity and gene transfer function,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Potency,"In Vitro Infectivity Assay, Transduction Assay, Reporter Gene Expression",Confirm biological activity and gene transfer function,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Empty Capsid Ratio,"AUC, Mass Photometry, TEM",Quantify proportion of empty versus full capsids,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Empty Capsid Ratio,"AUC, Mass Photometry, TEM",Quantify proportion of empty versus full capsids,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Empty Capsid Ratio,"AUC, Mass Photometry, TEM",Quantify proportion of empty versus full capsids,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Empty Capsid Ratio,"AUC, Mass Photometry, TEM",Quantify proportion of empty versus full capsids,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Genome Copy Number,"qPCR, ddPCR",Quantify vector genome dose,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 2,Genome Copy Number,"qPCR, ddPCR",Quantify vector genome dose,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 3,Genome Copy Number,"qPCR, ddPCR",Quantify vector genome dose,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Genome Copy Number,"qPCR, ddPCR",Quantify vector genome dose,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Genome Integrity,"Southern Blot, NGS",Assess integrity and structure of packaged genome,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Genome Integrity,"Southern Blot, NGS",Assess integrity and structure of packaged genome,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Genome Integrity,"Southern Blot, NGS",Assess integrity and structure of packaged genome,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Genome Integrity,"Southern Blot, NGS",Assess integrity and structure of packaged genome,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Aggregates,"DLS, SEC",Detect aggregation of viral particles,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Aggregates,"DLS, SEC",Detect aggregation of viral particles,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Aggregates,"DLS, SEC",Detect aggregation of viral particles,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Aggregates,"DLS, SEC",Detect aggregation of viral particles,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Host Cell Protein,ELISA,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Host Cell Protein,ELISA,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Host Cell Protein,ELISA,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Host Cell Protein,ELISA,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Host Cell DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Host Cell DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Host Cell DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Host Cell DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Residual Plasmid DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 2,Residual Plasmid DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Trend Monitoring
AAV,Phase 3,Residual Plasmid DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Commercial,Residual Plasmid DNA,qPCR,Control residual impurities from manufacturing process,FDA Gene Therapy CMC 2023,Specification
AAV,Phase 1,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
AAV,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
AAV,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
AAV,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
AAV,Phase 2,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
AAV,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
AAV,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
AAV,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
AAV,Phase 3,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
AAV,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
AAV,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
AAV,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
AAV,Commercial,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
AAV,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
AAV,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
AAV,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
CAR-T,Phase 1,Identity,"Flow Cytometry (Surface Markers), Transgene Detection (PCR), Cell Phenotyping",Confirm modified T-cell identity and transgene presence,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 2,Identity,"Flow Cytometry (Surface Markers), Transgene Detection (PCR), Cell Phenotyping",Confirm modified T-cell identity and transgene presence,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 3,Identity,"Flow Cytometry (Surface Markers), Transgene Detection (PCR), Cell Phenotyping",Confirm modified T-cell identity and transgene presence,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Identity,"Flow Cytometry (Surface Markers), Transgene Detection (PCR), Cell Phenotyping",Confirm modified T-cell identity and transgene presence,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Purity,Flow Cytometry (Cell Subset Characterization),Confirm cell population composition,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 2,Purity,Flow Cytometry (Cell Subset Characterization),Confirm cell population composition,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 3,Purity,Flow Cytometry (Cell Subset Characterization),Confirm cell population composition,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Purity,Flow Cytometry (Cell Subset Characterization),Confirm cell population composition,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Potency,"Cytotoxicity Assay, ELISPOT, Cytokine Release Assay",Confirm CAR-T functionality and target cell killing ability,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 2,Potency,"Cytotoxicity Assay, ELISPOT, Cytokine Release Assay",Confirm CAR-T functionality and target cell killing ability,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 3,Potency,"Cytotoxicity Assay, ELISPOT, Cytokine Release Assay",Confirm CAR-T functionality and target cell killing ability,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Potency,"Cytotoxicity Assay, ELISPOT, Cytokine Release Assay",Confirm CAR-T functionality and target cell killing ability,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Viability,"Flow Cytometry, Trypan Blue Exclusion",Confirm sufficient viable cells for patient administration,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 2,Viability,"Flow Cytometry, Trypan Blue Exclusion",Confirm sufficient viable cells for patient administration,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 3,Viability,"Flow Cytometry, Trypan Blue Exclusion",Confirm sufficient viable cells for patient administration,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Viability,"Flow Cytometry, Trypan Blue Exclusion",Confirm sufficient viable cells for patient administration,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Transduction Efficiency,"qPCR, Flow Cytometry",Confirm gene modification efficiency of T-cells,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 2,Transduction Efficiency,"qPCR, Flow Cytometry",Confirm gene modification efficiency of T-cells,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 3,Transduction Efficiency,"qPCR, Flow Cytometry",Confirm gene modification efficiency of T-cells,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Transduction Efficiency,"qPCR, Flow Cytometry",Confirm gene modification efficiency of T-cells,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Replication Competent Virus,qPCR,Ensure absence of replication competent retrovirus or lentivirus,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 2,Replication Competent Virus,qPCR,Ensure absence of replication competent retrovirus or lentivirus,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 3,Replication Competent Virus,qPCR,Ensure absence of replication competent retrovirus or lentivirus,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Replication Competent Virus,qPCR,Ensure absence of replication competent retrovirus or lentivirus,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Cytokine Profile,Multiplex Cytokine Assay,Characterize cytokine secretion profile for safety and efficacy,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 2,Cytokine Profile,Multiplex Cytokine Assay,Characterize cytokine secretion profile for safety and efficacy,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 3,Cytokine Profile,Multiplex Cytokine Assay,Characterize cytokine secretion profile for safety and efficacy,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Cytokine Profile,Multiplex Cytokine Assay,Characterize cytokine secretion profile for safety and efficacy,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Host Cell Protein,ELISA,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 2,Host Cell Protein,ELISA,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 3,Host Cell Protein,ELISA,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Host Cell Protein,ELISA,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Host Cell DNA,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 2,Host Cell DNA,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 3,Host Cell DNA,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Host Cell DNA,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Vector Residuals,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 2,Vector Residuals,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Trend Monitoring
CAR-T,Phase 3,Vector Residuals,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Commercial,Vector Residuals,qPCR,Control residuals from manufacturing process,FDA Cell Therapy Guidance 2023,Specification
CAR-T,Phase 1,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
CAR-T,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
CAR-T,Phase 1,Mycoplasma,Mycoplasma PCR,Ensure absence of mycoplasma contamination,USP <63>,Specification
CAR-T,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
CAR-T,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
CAR-T,Phase 2,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
CAR-T,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
CAR-T,Phase 2,Mycoplasma,Mycoplasma PCR,Ensure absence of mycoplasma contamination,USP <63>,Specification
CAR-T,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
CAR-T,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
CAR-T,Phase 3,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
CAR-T,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
CAR-T,Phase 3,Mycoplasma,Mycoplasma PCR,Ensure absence of mycoplasma contamination,USP <63>,Specification
CAR-T,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
CAR-T,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
CAR-T,Commercial,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
CAR-T,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
CAR-T,Commercial,Mycoplasma,Mycoplasma PCR,Ensure absence of mycoplasma contamination,USP <63>,Specification
CAR-T,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
CAR-T,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mRNA,Phase 1,Identity,"Capillary Electrophoresis, HPLC, LC-MS, Sequencing",Confirm mRNA sequence and integrity,EMA mRNA Guidance 2023,Specification
mRNA,Phase 2,Identity,"Capillary Electrophoresis, HPLC, LC-MS, Sequencing",Confirm mRNA sequence and integrity,EMA mRNA Guidance 2023,Specification
mRNA,Phase 3,Identity,"Capillary Electrophoresis, HPLC, LC-MS, Sequencing",Confirm mRNA sequence and integrity,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Identity,"Capillary Electrophoresis, HPLC, LC-MS, Sequencing",Confirm mRNA sequence and integrity,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Purity,"HPLC, Capillary Electrophoresis",Assess purity of mRNA transcript,EMA mRNA Guidance 2023,Specification
mRNA,Phase 2,Purity,"HPLC, Capillary Electrophoresis",Assess purity of mRNA transcript,EMA mRNA Guidance 2023,Specification
mRNA,Phase 3,Purity,"HPLC, Capillary Electrophoresis",Assess purity of mRNA transcript,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Purity,"HPLC, Capillary Electrophoresis",Assess purity of mRNA transcript,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Potency,"In Vitro Translation Assay, Reporter Protein Expression",Confirm translation efficiency and potency,EMA mRNA Guidance 2023,Specification
mRNA,Phase 2,Potency,"In Vitro Translation Assay, Reporter Protein Expression",Confirm translation efficiency and potency,EMA mRNA Guidance 2023,Specification
mRNA,Phase 3,Potency,"In Vitro Translation Assay, Reporter Protein Expression",Confirm translation efficiency and potency,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Potency,"In Vitro Translation Assay, Reporter Protein Expression",Confirm translation efficiency and potency,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Capping Efficiency,"LC-MS, HPLC",Confirm correct capping of mRNA for translation competency,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Capping Efficiency,"LC-MS, HPLC",Confirm correct capping of mRNA for translation competency,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Capping Efficiency,"LC-MS, HPLC",Confirm correct capping of mRNA for translation competency,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Capping Efficiency,"LC-MS, HPLC",Confirm correct capping of mRNA for translation competency,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Poly(A) Tail Length,"LC-MS, PCR-based Tail Length Assay",Monitor tail length critical for stability and translation,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Poly(A) Tail Length,"LC-MS, PCR-based Tail Length Assay",Monitor tail length critical for stability and translation,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Poly(A) Tail Length,"LC-MS, PCR-based Tail Length Assay",Monitor tail length critical for stability and translation,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Poly(A) Tail Length,"LC-MS, PCR-based Tail Length Assay",Monitor tail length critical for stability and translation,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Double-Stranded RNA,"ELISA, HPLC",Control innate immune activation risk due to dsRNA impurities,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Double-Stranded RNA,"ELISA, HPLC",Control innate immune activation risk due to dsRNA impurities,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Double-Stranded RNA,"ELISA, HPLC",Control innate immune activation risk due to dsRNA impurities,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Double-Stranded RNA,"ELISA, HPLC",Control innate immune activation risk due to dsRNA impurities,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Residual DNA Template,qPCR,Confirm removal of DNA template post-IVT reaction,EMA mRNA Guidance 2023,Specification
mRNA,Phase 2,Residual DNA Template,qPCR,Confirm removal of DNA template post-IVT reaction,EMA mRNA Guidance 2023,Specification
mRNA,Phase 3,Residual DNA Template,qPCR,Confirm removal of DNA template post-IVT reaction,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Residual DNA Template,qPCR,Confirm removal of DNA template post-IVT reaction,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Residual Enzymes,Activity Assays or ELISA,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Residual Enzymes,Activity Assays or ELISA,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Residual Enzymes,Activity Assays or ELISA,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Residual Enzymes,Activity Assays or ELISA,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Residual Reagents,HPLC,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Residual Reagents,HPLC,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Residual Reagents,HPLC,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Residual Reagents,HPLC,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Residual Solvents,GC-MS,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 2,Residual Solvents,GC-MS,Control manufacturing residuals,EMA mRNA Guidance 2023,Trend Monitoring
mRNA,Phase 3,Residual Solvents,GC-MS,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Commercial,Residual Solvents,GC-MS,Control manufacturing residuals,EMA mRNA Guidance 2023,Specification
mRNA,Phase 1,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
mRNA,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mRNA,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mRNA,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mRNA,Phase 1,Osmolality,Osmometer,Confirm formulation osmolality,ICH Q6B,Specification
mRNA,Phase 2,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
mRNA,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mRNA,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mRNA,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mRNA,Phase 2,Osmolality,Osmometer,Confirm formulation osmolality,ICH Q6B,Specification
mRNA,Phase 3,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
mRNA,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mRNA,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mRNA,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mRNA,Phase 3,Osmolality,Osmometer,Confirm formulation osmolality,ICH Q6B,Specification
mRNA,Commercial,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
mRNA,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
mRNA,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
mRNA,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
mRNA,Commercial,Osmolality,Osmometer,Confirm formulation osmolality,ICH Q6B,Specification
ADC,Phase 1,Identity,"Peptide Mapping, LC-MS, DAR Analysis",Confirm correct antibody sequence and drug conjugation structure,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 2,Identity,"Peptide Mapping, LC-MS, DAR Analysis",Confirm correct antibody sequence and drug conjugation structure,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 3,Identity,"Peptide Mapping, LC-MS, DAR Analysis",Confirm correct antibody sequence and drug conjugation structure,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Commercial,Identity,"Peptide Mapping, LC-MS, DAR Analysis",Confirm correct antibody sequence and drug conjugation structure,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 1,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis",Assess purity and aggregation profile of ADC,ICH Q6B,Specification
ADC,Phase 2,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis",Assess purity and aggregation profile of ADC,ICH Q6B,Specification
ADC,Phase 3,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis",Assess purity and aggregation profile of ADC,ICH Q6B,Specification
ADC,Commercial,Purity,"SEC-UPLC, CE-SDS, Capillary Electrophoresis",Assess purity and aggregation profile of ADC,ICH Q6B,Specification
ADC,Phase 1,Potency,"Binding Assay, Cytotoxicity Assay (In vitro bioassay)",Confirm binding and cytotoxic function of ADC,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 2,Potency,"Binding Assay, Cytotoxicity Assay (In vitro bioassay)",Confirm binding and cytotoxic function of ADC,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 3,Potency,"Binding Assay, Cytotoxicity Assay (In vitro bioassay)",Confirm binding and cytotoxic function of ADC,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Commercial,Potency,"Binding Assay, Cytotoxicity Assay (In vitro bioassay)",Confirm binding and cytotoxic function of ADC,"ICH Q6B, FDA ADC Guidance",Specification
ADC,Phase 1,DAR (Drug-Antibody Ratio),"LC-MS, UV Spectroscopy, HIC-HPLC",Quantify average number of drug molecules conjugated per antibody,FDA ADC Guidance,Trend Monitoring
ADC,Phase 2,DAR (Drug-Antibody Ratio),"LC-MS, UV Spectroscopy, HIC-HPLC",Quantify average number of drug molecules conjugated per antibody,FDA ADC Guidance,Trend Monitoring
ADC,Phase 3,DAR (Drug-Antibody Ratio),"LC-MS, UV Spectroscopy, HIC-HPLC",Quantify average number of drug molecules conjugated per antibody,FDA ADC Guidance,Specification
ADC,Commercial,DAR (Drug-Antibody Ratio),"LC-MS, UV Spectroscopy, HIC-HPLC",Quantify average number of drug molecules conjugated per antibody,FDA ADC Guidance,Specification
ADC,Phase 1,Free Drug,"HPLC, LC-MS",Quantify unbound cytotoxic drug,FDA ADC Guidance,Specification
ADC,Phase 2,Free Drug,"HPLC, LC-MS",Quantify unbound cytotoxic drug,FDA ADC Guidance,Specification
ADC,Phase 3,Free Drug,"HPLC, LC-MS",Quantify unbound cytotoxic drug,FDA ADC Guidance,Specification
ADC,Commercial,Free Drug,"HPLC, LC-MS",Quantify unbound cytotoxic drug,FDA ADC Guidance,Specification
ADC,Phase 1,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform heterogeneity due to conjugation,ICH Q6B,Trend Monitoring
ADC,Phase 2,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform heterogeneity due to conjugation,ICH Q6B,Trend Monitoring
ADC,Phase 3,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform heterogeneity due to conjugation,ICH Q6B,Specification
ADC,Commercial,Charge Variants,"icIEF, Ion Exchange Chromatography",Detect isoform heterogeneity due to conjugation,ICH Q6B,Specification
ADC,Phase 1,Glycosylation Profile,"HILIC-UPLC, LC-MS",Characterize glycan profile on antibody,ICH Q6B,Trend Monitoring
ADC,Phase 2,Glycosylation Profile,"HILIC-UPLC, LC-MS",Characterize glycan profile on antibody,ICH Q6B,Trend Monitoring
ADC,Phase 3,Glycosylation Profile,"HILIC-UPLC, LC-MS",Characterize glycan profile on antibody,ICH Q6B,Specification
ADC,Commercial,Glycosylation Profile,"HILIC-UPLC, LC-MS",Characterize glycan profile on antibody,ICH Q6B,Specification
ADC,Phase 1,Deamidation,Peptide Mapping LC-MS,Detect deamidation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 2,Deamidation,Peptide Mapping LC-MS,Detect deamidation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 3,Deamidation,Peptide Mapping LC-MS,Detect deamidation as degradation product,ICH Q6B,Specification
ADC,Commercial,Deamidation,Peptide Mapping LC-MS,Detect deamidation as degradation product,ICH Q6B,Specification
ADC,Phase 1,Oxidation,Peptide Mapping LC-MS,Detect oxidation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 2,Oxidation,Peptide Mapping LC-MS,Detect oxidation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 3,Oxidation,Peptide Mapping LC-MS,Detect oxidation as degradation product,ICH Q6B,Specification
ADC,Commercial,Oxidation,Peptide Mapping LC-MS,Detect oxidation as degradation product,ICH Q6B,Specification
ADC,Phase 1,Fragmentation,SEC-UPLC,Detect fragmentation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 2,Fragmentation,SEC-UPLC,Detect fragmentation as degradation product,ICH Q6B,Trend Monitoring
ADC,Phase 3,Fragmentation,SEC-UPLC,Detect fragmentation as degradation product,ICH Q6B,Specification
ADC,Commercial,Fragmentation,SEC-UPLC,Detect fragmentation as degradation product,ICH Q6B,Specification
ADC,Phase 1,Host Cell Protein,ELISA,Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 2,Host Cell Protein,ELISA,Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 3,Host Cell Protein,ELISA,Control process-related impurities,FDA ADC Guidance,Specification
ADC,Commercial,Host Cell Protein,ELISA,Control process-related impurities,FDA ADC Guidance,Specification
ADC,Phase 1,Host Cell DNA,qPCR,Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 2,Host Cell DNA,qPCR,Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 3,Host Cell DNA,qPCR,Control process-related impurities,FDA ADC Guidance,Specification
ADC,Commercial,Host Cell DNA,qPCR,Control process-related impurities,FDA ADC Guidance,Specification
ADC,Phase 1,Linker-Drug Impurities,"HPLC, LC-MS",Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 2,Linker-Drug Impurities,"HPLC, LC-MS",Control process-related impurities,FDA ADC Guidance,Trend Monitoring
ADC,Phase 3,Linker-Drug Impurities,"HPLC, LC-MS",Control process-related impurities,FDA ADC Guidance,Specification
ADC,Commercial,Linker-Drug Impurities,"HPLC, LC-MS",Control process-related impurities,FDA ADC Guidance,Specification
ADC,Phase 1,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
ADC,Phase 1,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
ADC,Phase 1,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
ADC,Phase 1,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
ADC,Phase 2,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
ADC,Phase 2,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
ADC,Phase 2,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
ADC,Phase 2,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
ADC,Phase 3,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
ADC,Phase 3,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
ADC,Phase 3,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
ADC,Phase 3,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
ADC,Commercial,Sterility,USP <71>,Ensure product sterility,USP <71>,Specification
ADC,Commercial,Endotoxin,LAL USP <85>,Control pyrogen risk,USP <85>,Specification
ADC,Commercial,Appearance,Visual Inspection,"Appearance check for visible particles, color",ICH Q6B,Specification
ADC,Commercial,pH,pH Meter,Confirm formulation pH,ICH Q6B,Specification
